Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag BioNxt Solutions seeks exclusive licensing for its oral thin film treatment in Eurasian and European markets, targeting high-MS regions.

flag BioNxt Solutions Inc. has signed a non-binding letter of intent to explore exclusive licensing for its sublingual cladribine oral thin film in one or more Eurasian Patent Organization member states, following patent grants in both the Eurasian region and Europe. flag The EAPO patent, effective November 2025, covers eight countries with over 200 million people and expires in 2043. flag The EPO granted a related patent on March 11, 2026, potentially covering up to 39 European countries through 2043. flag The 60-day negotiation period focuses on a potential deal involving upfront payments, royalties, and collaboration on regulatory, manufacturing, and commercialization efforts. flag The company is targeting markets with high rates of neurological and autoimmune conditions like Multiple Sclerosis, affecting about 2.9 million people globally.

11 Articles